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GENERAL THORACIC SURGERY 
EDITORIAL ON COMBINED THERAPY FOR SQUAMOUS CELL CARCINOMA OF THE 
ESOPHAGUS 
David B. Skinner, MD 
T he next two articles in this issue of the Journal are two important Studies On Combined therapy 
for squamous cell carcinoma of the esophagus. In 
the Japan Clinical Onco!ogy Group study, 1postop- 
erative chemotherapy with cisplatin and vindesine 
are compared with surgery alone for patients having 
undergone a transthoracic esophagectomy with ex- 
tensive lymphadenectomy for cancer of the thoracic 
esophagus. Surgical survivors were randomized to 
receive postoperative chemotherapy or no further 
therapy. The sample size was sufficient o show a 
clinical difference if such occurred. No difference in 
long-term survival was detected between those 
treated by surgery alone and those treated by similar 
operations plus postoperative chemotherapy. Sur- 
vival was slightly better in those with diseased lymph 
nodes treated by chemotherapy compared with the 
no treatment group, but the difference was not 
significant. 
In the Hong Kong prospective randomized trial, 2 
preoperative chemotherapy with cisplatin and 5-flu- 
orouracil followed by resection was compared with 
the results of surgery alone for squamous cell carci- 
noma of the esophagus. This study was not limited 
to patients with potentially curable disease, and 11% 
in the chemotherapy and 5% in the control group 
did not undergo surgical treatment. Again, the 
long-term survival data showed no significant differ- 
ence between the group randomized to receive 
chemotherapy versus the surgery-alone group. As in 
several other recent publications, 3' 4 those patients 
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responding to chemotherapy had a better prognosis 
after surgery than did the nonresponders who un- 
derwent resection. This difference was highly signif- 
icant. Those responding to chemotherapy had a 
median survival significantly longer than did the 
entire surgery-alone group. Patients receiving che- 
motherapy (58% of the 60 undergoing resection, or 
47% of those randomized to receive chemotherapy) 
had a partial or complete response and underwent 
clinical downstaging before the operation. However, 
for those patients undergoing curative resection (R 0 
with or without preoperative therapy), no significant 
difference in survival could be detected, although 
the trend was favorable for the preoperative chemo- 
therapy group. Clinical staging in the Hong Kong 
group did not include computed tomographic s ans 
or endoscopic ultrasonography. These techniques 
are generally thought o improve the preoperative 
staging and define comparable patient groups more 
precisely. 
What lessons can be learned from these two impor- 
tant randomized trials? Inasmuch as no prospective 
randomized trial of preoperative orpostoperative ad- 
juvant therapy for squamous cell carcinoma proves 
that overall results are better than with surgery alone, 
surgery alone remains the preferred treatment of 
choice. A number of articles have now been published 
which demonstrate hat more extensive primary sur- 
gery for potentially curable disease yields better esults 
than the limited types of resections performed rou- 
tinely in the past and still in wide use. 5-7 
The role of adjuvant chemotherapy has value only 
in those patients who respond to such treatment. 
Unfortunately, these patients cannot be identified 
with any certainty before the trial of chemotherapy. 
Because there is no tumor 0n which to judge 
response in protocols offering postoperative treat- 
ment, there is no basis for recommending postoper- 
ative chemotherapy rophylactically after curative 
esophagectomy. A better argument can be made for 
not giving postoperative adjuvant chemotherapy un- 
til an actual recurrence develops. At such time 
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postoperative chemotherapy/radiation therapy for 
the recurrence can be recommended. 
In the arguments concerning preoperative chemo- 
therapy, the Hong Kong group found that earlier or 
more favorable stages of cancer were more likely to 
respond partially or completely to preoperative che- 
motherapy. This is also the group of patients who 
have the best chance for survival after curative 
surgery alone. Inasmuch as no significant difference 
was detected in the reSults between surgery alone 
versus chemotherapy lus surgery in the more fa- 
vorable cases, it is hard to justify any routine use of 
preoperative chemotherapy. 
In carefully controlled trials performed in inves- 
tigative centers, the opportunity remains to study 
the relationship between complete and partial re- 
sponders to a variety and increasing numbers of 
potential markers for tumor responsiveness. If a 
chemotherapy response could be predicted by a 
pretreatment marker, those patients who would 
respond would certainly be candidates for preoper- 
ative therapy. Therefore it is essential that such 
trials continue, but only in the setting of randomized 
trials in which study of multiple tumor markers can 
be carried out and correlated with chemotherapy 
response. Preoperative Chemotherapy is not justifi- 
able as standard practice at this time. 
Comparison of these two trials points out other 
difficulties in comparing results from different 
groups or centers. The extent of surgery performed 
in these two trials is different. The dosages of 
cisplatin Used were different. And the methods of 
staging used were different both technologically and 
in the system of staging. In recent years the outlook 
for patients with esophageal cancer undergoing 
treatment has improved somewhat because of ad- 
vances in surgical technique, including a more thor- 
ough remoVal of the primary tumor and its lym- 
phatic drainage to the neck, mediastinum, and 
abdomen. For selected patients who respond to 
chemotherapy, the outlook is also improved. These 
observations instruct us in the standardization of 
surgical techniques and they encourage the contin- 
uation of research trials with new and better types of 
chemotherapy yet to be introduced, improved meth- 
ods for pretreatment s aging, and identification of 
markers to determine which patients have a favor- 
able prognosis for combined therapy. 
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